Longevity Capital Chases Skin, Blood Pressure and GLP-1 Access

Beiersdorf's new $100M+ venture fund and a $20M raise for Rapalogix, which targets cellular aging pathways like TORC1, mark a real capital shift toward 'skin longevity' as a category distinct from conventional anti-aging skincare. Expect the science to surface first at destination spas and medical-wellness properties already built around diagnostics — think Clinique La Prairie, SHA Wellness, and Six Senses — as premium add-on packages rather than standard treatments. The commercial upside is real, but so is the risk: analysts covering the space are already flagging 'longevity washing,' where marketing outpaces evidence. Advisors fielding client interest in these programs should ask operators directly what's being measured, what's diagnostic versus cosmetic, and what outcomes data actually backs the price tag before positioning a package as more than a spa treatment with a scientific veneer.

Two device raises underline where longevity-adjacent venture capital is flowing: blood-pressure wearable Hilo closed a $19M Series B extension (bringing it to $119M total), and health-monitoring toilet-seat startup Casana raised $46M. Both bet that clinics and consumers want continuous biometric data. At the same time, a countervailing 'unquantified self' movement is gaining visibility — travelers explicitly seeking retreats that dial back tracking rather than add it. That split is a positioning cue: operators building guest-screening protocols around new diagnostic hardware are chasing one audience, while digital-detox and low-tech retreat programs are chasing the opposite one. Advisors should ask new intake questions when booking longevity or retreat programs — whether a client wants data-forward monitoring or wants to leave the wearables at home — rather than assuming every wellness traveler wants more measurement.

eMed, now valued near $2B after a $200M raise, is lobbying employers to add GLP-1 coverage as a standard workplace wellness benefit, with Tom Brady serving as chief wellness officer for the pitch. That's a mainstreaming move: medical weight-loss access shifting from individual prescription to corporate benefit line item. For advisors handling executive and corporate wellness-retreat business, this raises the odds that clients arrive already on a GLP-1 protocol or expecting a program built around one. Medical-wellness properties that already integrate GLP-1 protocols — SHA Wellness, Lanserhof, Mayrlife among them — are best positioned to absorb that demand without friction. Worth flagging to corporate wellness buyers now, before it becomes an expected line item in RFPs rather than a differentiator.